Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma
Status:
Completed
Trial end date:
2021-02-07
Target enrollment:
Participant gender:
Summary
The aim of this study is to observe the efficacy, safety, postoperative pathological response
rate and survival benefit of immume checkpoint inhibitor PD-1 SHR1210 combined with
chemotherapy in neoadjuvant therapy of locally advanced resectable gastric and
gastroesophageal junction adenocarcinoma. In addition ，the investigators will explore the
relationship between the immunophenotype of gastric cancer and the efficacy and drug
resistance of immunotherapy combined with chemotherapy, and screen out biomarkers that can
predict the efficacy of immunotherapy.